Aberrant Glycosylation Signature in Pancreatic Cancer

胰腺癌中的异常糖基化特征

• 批准号: 8043791
• 负责人: Teresa A Brentnall
• 金额: $ 18.8万
• 依托单位: UNIVERSITY OF WASHINGTON
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-01-01 至 2012-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8043791
• 关键词: Age; Biological Markers; Blood; Cancer Detection; Cancer Etiology; Cancer Patient; Cessation of life; Classification; Complex; Detection; Development; Diagnosis; Disease; Early Detection Research Network; Early Diagnosis; Future; Glycopeptides; Glycoproteins; Goals; Grant; Guidelines; Individual; Investigation; Malignant - descriptor; Malignant Neoplasms; Malignant neoplasm of pancreas; Mass Spectrum Analysis; Measures; Membrane; Molecular; Molecular Profiling; N-Glycosylation Site; Neoplasm Metastasis; Outcome; Pancreatitis; Pattern; Plasma; Protein Glycosylation; Proteins; Proteomics; Sampling; Sensitivity and Specificity; Staging; Survival Rate; Technology; Testing; United States; Vascular blood supply; base; cancer therapy; case control; cohort; disease diagnosis; glycosylation; improved; tool; tumor; tumor progression

DESCRIPTION (provided by applicant): Pancreatic cancer is the fourth leading cause of cancer death in the United State. One of the major obstacles for improving the outcome in pancreatic cancer treatment arises from the difficulty in diagnosing the disease at an early stage, a goal that could markedly improve the survival rate. Abnormal glycosylation of proteins is often associated with malignant transformation, and has been recognized as a hallmark of pancreatic cancer. In this proposal, we will first apply quantitative proteomics to reveal dysregulated glycosylations associated with pancreatic cancer in plasma. We will then apply a highly sensitive platform technology to quantitatively detect aberrant glycosylations associated with pancreatic cancer in a cohort of cases and controls, and test the hypothesis of using aberrant glycosylation pattern as a molecular fingerprint for pancreatic cancer recognition. PUBLIC HEALTH RELEVANCE: Pancreatic cancer is the fourth leading cause of cancer death in the United State and it is very difficult to diagnosis at an early stage when the disease is curable. Biomarkers are desperately needed for early diagnosis of pancreatic cancer. Aberrant protein glycosylation associated with pancreatic cancer can potentially serve as a molecular signature for pancreatic cancer recognition.

描述（由申请人提供）：胰腺癌是美国癌症死亡的第四大原因。改善胰腺癌治疗结果的主要障碍之一来自早期诊断疾病的困难，这是一个可以显着提高生存率的目标。蛋白质的异常糖基化通常与恶性转化相关，并且已被认为是胰腺癌的标志。在这个提议中，我们将首先应用定量蛋白质组学来揭示与胰腺癌相关的血浆糖基化失调。然后，我们将应用一种高度敏感的平台技术来定量检测一组病例和对照中与胰腺癌相关的异常糖基化，并测试使用异常糖基化模式作为胰腺癌识别的分子指纹的假设。 公共卫生相关性：胰腺癌是美国癌症死亡的第四大原因，当疾病可治愈时，很难在早期诊断。胰腺癌的早期诊断迫切需要生物标志物。与胰腺癌相关的异常蛋白质糖基化可能作为胰腺癌识别的分子标记。